A New S&P 500 Bull Market Just Began: 3 No-Brainer Stocks to Buy Hand Over Fist
https://www.fool.com/investing/2024/01/22/sp-500-bull-market-no-brainer-stocks-to-buy/?source=iedfolrf0000001
Jan 22, 2024 - These stocks seem likely to keep up their winning ways.
0
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
https://www.zacks.com/stock/news/2212227/biotech-stock-roundup-vrtx-crsp-gene-therapy-label-expansion-allk-falls-on-update?cid=CS-ZC-FT-analyst_blog|stock_roundup-2212227
Jan 18, 2024 - Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.
0
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2211744/vertex-pharmaceuticals-vrtx-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2211744
Jan 17, 2024 - Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $433.76, signifying a -0.85% move from its prior day's close.
0
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
https://www.zacks.com/stock/news/2211622/vertex-vrtx-crsp-s-casgevy-gets-fda-nod-for-thalassemia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2211622
Jan 17, 2024 - This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
0
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
https://www.fool.com/investing/2024/01/15/heres-why-crispr-therapeutics-stock-rose-54-last-y/?source=iedfolrf0000001
Jan 15, 2024 - Key regulatory developments sent this biotech stock higher.
0
Here's How Much You'd Have If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago
https://www.zacks.com/stock/news/2207791/here-s-how-much-you-d-have-if-you-invested-1000-in-vertex-pharmaceuticals-a-decade-ago?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2207791
Jan 09, 2024 - Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
0
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
https://www.zacks.com/stock/news/2207133/will-vertex-vrtx-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2207133
Jan 08, 2024 - Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0
PBYI vs. VRTX: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2207091/pbyi-vs-vrtx-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2207091
Jan 08, 2024 - PBYI vs. VRTX: Which Stock Is the Better Value Option?
0
The Best Stocks to Invest $1,000 in Right Now
https://www.fool.com/investing/2024/01/04/the-best-stocks-to-invest-1000-in-right-now/?source=iedfolrf0000001
Jan 04, 2024 - It's not too late to get in on these market beaters.
0
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
https://www.fool.com/investing/2023/12/31/1-cathie-wood-stock-worth-buying-hand-over-fist-in/?source=iedfolrf0000001
Dec 31, 2023 - Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name.
0